Accelerated Approval: How The Aduhelm Probes Will, And Won’t, Impact The Debate

 
• By Sarah Karlin-Smith
  
FDA under OIG microscope (design by Nielsen Hobbs)
FDA is undergoing two reviews related to its controversial approval of Biogen’s Aduhelm. • Source: Nielsen Hobbs; the Pink Sheet | Alamy image
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Agency Leadership